SEARCH:   Advanced

Blood, 15 November 2003, Vol. 102, No. 10, pp. 3514-3520. Prepublished online as a Blood First Edition Paper on July 31, 2003; DOI 10.1182/blood-2003-01-0055. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-01-0055v1 102/10/3514    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Jilani, I. Articles by Albitar, M. Search for Related Content PubMed PubMed Citation Articles by Jilani, I. Articles by Albitar, M. Related Collections Neoplasia Immunotherapy Clinical Trials and Observations Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia Iman Jilani, Susan O'Brien, Taghi Manshuri, Deborah A. Thomas, Vilmos A. Thomazy, Maha Imam, Sana Naeem, Srdan Verstovsek, Hagop Kantarjian, Francis Giles, Michael Keating, and Maher Albitar From the Departments of Hematopathology and Leukemia, University of Texas MD Anderson Cancer Center, Houston. Lymphoid cells in most patients with chronic lymphocytic leukemia (CLL), when treated with rituximab, become CD20-. This is thought to be due to masking of CD20 by rituximab. We used specific antimouse immunoglobulin antibodies to detect rituximab on the surface of CLL lymphocytes and we demonstrate that rituximab is rarely detectable after therapy. Only 3 of 65 patients with CLL had rituximab detectable on their lymphocytes after rituximab therapy despite the fact that most had no detectable CD20 expression. In vitro mixing of CLL or Raji cells with rituximab demonstrated that rituximab was detectable on the surface of cells due to its binding to CD20. However, the addition of plasma led to the down-modulation of CD20 expression, and the rituximab became undetectable. This down-modulation of CD20 protein expression was associated with a down-modulation of CD20 mRNA. CLL cells that lost their CD20 expression regained CD20 expression after 24 hours in culture. These data suggest that rituximab therapy leads to a substantial but transient down-modulation of CD20 expression and that negativity for CD20 in cells from patients treated with rituximab is not necessarily due to CD20 masking. The importance of this down-modulation in the efficacy of current therapy with rituximab needs further investigation. (Blood. 2003;102: 3514-3520) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Apparent modulation of CD20 by rituximab: an alternative explanation Mark S. Cragg, Mike C. Bayne, Timothy M. Illidge, Thomas Valerius, Peter W. N. Johnson, Martin J. Glennie, Iman Jilani, and Maher Albitar Blood 2004 103: 3989-3991. [Full Text] [PDF] This article has been cited by other articles: M. J. Leandro, N. Cooper, G. Cambridge, M. R. Ehrenstein, and J. C. W. Edwards Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy Rheumatology, January 1, 2007; 46(1): 29 - 36. [Abstract] [Full Text] [PDF] K N Naresh, I Lampert, R Hasserjian, D Lykidis, K Elderfield, D Horncastle, N Smith, W Murray-Brown, and G W Stamp Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol. J. Clin. Pathol., September 1, 2006; 59(9): 903 - 911. [Abstract] [Full Text] [PDF] J. L. Teeling, W. J. M. Mackus, L. J. J. M. Wiegman, J. H. N. van den Brakel, S. A. Beers, R. R. French, T. van Meerten, S. Ebeling, T. Vink, J. W. Slootstra, et al. The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20 J. Immunol., July 1, 2006; 177(1): 362 - 371. [Abstract] [Full Text] [PDF] J. K. Bubien, H.-L. Ji, G. Y. Gillespie, C. M. Fuller, J. M. Markert, T. B. Mapstone, and D. J. Benos Cation selectivity and inhibition of malignant glioma Na+ channels by Psalmotoxin 1 Am J Physiol Cell Physiol, November 1, 2004; 287(5): C1282 - C1291. [Abstract] [Full Text] [PDF] M. S. Cragg, M. B. Bayne, A. L. Tutt, R. R. French, S. Beers, M. J. Glennie, and T. M. Illidge A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells Blood, October 15, 2004; 104(8): 2540 - 2542. [Abstract] [Full Text] [PDF] J. L. Teeling, R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. H. I. Parren, C. E. Hack, M. Dechant, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas Blood, September 15, 2004; 104(6): 1793 - 1800. [Abstract] [Full Text] [PDF] M. S. Cragg, M. C. Bayne, T. M. Illidge, T. Valerius, P. W. N. Johnson, M. J. Glennie, I. Jilani, and M. Albitar Apparent modulation of CD20 by rituximab: an alternative explanation Blood, May 15, 2004; 103(10): 3989 - 3991. [Full Text] [PDF] Y.-T. Tai, L. P. Catley, C. S. Mitsiades, R. Burger, K. Podar, R. Shringpaure, T. Hideshima, D. Chauhan, M. Hamasaki, K. Ishitsuka, et al. Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications Cancer Res., April 15, 2004; 64(8): 2846 - 2852. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020